- Home
- INTU vs AMGN Comparison
INTU vs AMGN Comparison
Compare INTU & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTU
- AMGN
- Stock Information
- Founded
- INTU 1983
- AMGN 1980
- Country
- INTU United States
- AMGN United States
- Employees
- INTU N/A
- AMGN N/A
- Industry
- INTU Computer Software: Prepackaged Software
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INTU Technology
- AMGN Health Care
- Exchange
- INTU Nasdaq
- AMGN Nasdaq
- Market Cap
- INTU 169.8B
- AMGN 156.2B
- IPO Year
- INTU 1993
- AMGN N/A
- Fundamental
- Price
- INTU $565.47
- AMGN $303.01
- Analyst Decision
- INTU Buy
- AMGN Buy
- Analyst Count
- INTU 21
- AMGN 21
- Target Price
- INTU $726.45
- AMGN $322.26
- AVG Volume (30 Days)
- INTU 1.8M
- AMGN 3.0M
- Earning Date
- INTU 02-25-2025
- AMGN 02-04-2025
- Dividend Yield
- INTU 0.74%
- AMGN 3.14%
- EPS Growth
- INTU 12.51
- AMGN N/A
- EPS
- INTU 10.28
- AMGN 7.56
- Revenue
- INTU $16,590,000,000.00
- AMGN $33,424,000,000.00
- Revenue This Year
- INTU $14.52
- AMGN $5.39
- Revenue Next Year
- INTU $12.30
- AMGN $1.55
- P/E Ratio
- INTU $55.00
- AMGN $40.08
- Revenue Growth
- INTU 12.48
- AMGN 18.57
- 52 Week Low
- INTU $557.29
- AMGN $253.30
- 52 Week High
- INTU $714.78
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- INTU 32.93
- AMGN 65.77
- Support Level
- INTU $568.71
- AMGN $289.00
- Resistance Level
- INTU $586.10
- AMGN $298.35
- Average True Range (ATR)
- INTU 13.79
- AMGN 7.14
- MACD
- INTU -0.28
- AMGN 0.17
- Stochastic Oscillator
- INTU 8.93
- AMGN 75.16
About INTU Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of US market share for small-business accounting and do-it-yourself tax-filing software.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.